The FDA has approved Grastek, a second sublingual immunotherapy to 
treat grass pollen allergies. (The first sublingual immunotherapy for 
grass allergies, Oralair, was approved earlier this month.) The new 
tablet contains Timothy grass extracts and is indicated for patients 
aged 5 to 65 years.

In December 2013, FDA advisers called for postapproval studies to test 
Grastek’s safety in children aged 5 to 11 years, citing side effects 
such as lip swelling and oral blistering.

Reuters story (Free)
By Kristin J. Kelley